Advances and challenges in blood cancer drug discovery
Drug Discovery World speaks to companies at the cutting edge of innovation in blood cancer therapeutics.
The prognosis for patients with blood cancers has improved dramatically since the turn of the century. Thanks to an ever-growing array of treatments becoming available, there has been significant progress in treating B cell leukaemias like acute lymphoblastic leukaemia (B-ALL), as well as diffuse large B-cell lymphoma (DLBCL), plus both Hodgkin lymphoma and non-Hodgkin lymphoma.
These advances are due in large part to the application of new treatment strategies underpinned by targeted approaches. The utilisation of key targets like CD19 and CD20, which are heavily expressed on the surface of B cells, has been vital.
Such targets have been used in different modalities such as monoclonal antibodies like rituximab, as well as bispecific antibodies, antibody-drug conjugates (ADCs) and CAR-T cell therapies – modalities that did not exist for patients 25 years ago.
The last quarter of a century has therefore been a good one in terms of making ground in the battle against blood cancers.
But the fight is far from won. Advances have been much less impressive in myeloid malignancies, including – most notably – acute myeloid leukaemia (AML), as well as the related myelodysplastic syndrome (MDS). Progress in the treatment of (relatively rare) T cell blood cancers has likewise been muted.
So what is happening now, in terms of developments in the lab and the clinic, and how optimistic (or otherwise) are leading researchers in the space?
DDW: How encouraged are you by recent progress in blood cancer treatments?
Dr Stefano Gullà, CSO, Kling Bio: I am highly encouraged by the advancements in blood cancer treatments, particularly the development of targeted therapies like CAR-T cells, bispecific antibodies, and small molecule inhibitors such as BTK and FLT3 inhibitors. These therapies have shown remarkable efficacy in improving survival rates and quality of life for patients with previously untreatable or relapsed blood cancers. However, not all indications have benefitted equally from targeted therapies with outcomes in myeloid malignancies such as AML still lagging behind B cell neoplasms, mostly due to the lack of suitable targets.
Dr Dongzhou Jeffery Liu, CEO, Heidelberg Pharma Since the 1990s, there has been remarkable progress in blood cancer treatments, and survival rates have significantly increased. Existing drugs have been repurposed in new combinations and for new indications, resulting in significant improvements. Additionally, groundbreaking developments in the field of immunotherapy and targeted therapy have further advanced the treatment of blood cancers.
However, unlike solid tumours, which are confined to a specific area of the body, blood cancers are more difficult to treat because they circulate in the body as liquid tumours.
Heidelberg Pharma’s novel Amanitin-based anti-drug conjugates (ADCs) can identify diseased cells, penetrate them, and kill the cancer cells.
Jeremy Skillington, CEO, Poolbeg Pharma: Blood cancer drug development is an incredibly exciting place right now. There have been many life-changing medications approved which are transforming survival expectations in cancers. Targeted therapies and immunotherapies are offering superior quality of life to patients by limiting off target toxicities. Blood cancer research has long led the way in advancing new treatments — in fact, the first cancer immunotherapy was developed for blood cancers and advancements in cancer immunotherapies are continuing with the development of tri-specific antibodies and in vivo cell therapies.
Michael Lahn, CMO, iOnctura: In recent decades, practice-changing treatments in blood cancers have improved survival and quality of life of patients. There are three main pharmaceutical treatment approaches which may continue to further transform current treatments: (a) small molecules targeting specific signalling pathways (such as Bruton Tyrosine Kinase (BTK) inhibitors); (b) immune modulatory agents (such as bispecific agents which enhance immune responses); (c) cellular therapies, such as CAR-T cells.
DDW: What are some of the biggest challenges facing drug discovery in blood cancers today?
Dr Stefano Gullà, CSO, Kling Bio: The biggest challenges include tumour heterogeneity, resistance mechanisms, and the complexity of the tumour microenvironment. Additionally, translating preclinical findings into effective clinical therapies remains a hurdle, as does managing the toxicities associated with novel immunotherapies like CAR-T cells.
Dr Dongzhou Jeffery Liu, CEO, Heidelberg Pharma: Blood cancers, including lymphoma and multiple myeloma, originate in bone marrow and are hard to detect at an early stage. The intricate microenvironment presents considerable challenges for conventional therapies such as chemotherapy, immunotherapy, radiotherapy, and haematopoietic stem cell transplantation. These approaches often have poor specificity and low bioavailability, resulting in systemic toxicity and suboptimal treatment outcomes.
Jeremy Skillington, CEO, Poolbeg Pharma: One of the biggest challenges has been enabling immunotherapies in polyclonal diseases such as AML. Some cancers don’t express a single target that differentiates them from healthy tissues, making it challenging to develop durable and safe therapies. But there are research groups actively working on solutions for these traditionally ‘hard-to-treat’ cancers. In conditions where there has been more progress, the challenge has become identifying proxy endpoints for trials. Median progression-free survival is exceeding 10-15 years in indications like myeloma, so traditional endpoints don’t work in these conditions anymore.
Michael Lahn, CMO, iOnctura: Genetic and molecular diversity across subtypes makes it difficult to develop broadly effective therapies, especially in those blood cancers where multiple cancer-promoting signalling pathways are active and multi-drug treatments are too toxic for patients. To expediate clinical development it may be useful to rely on novel biomarkers which may have a reasonable association with clinical benefit. Biomarkers, such as those detecting minimal residual disease, may point towards an innovative endpoint and encourage the clinical evaluation of combination or the sequencing of novel agents.
DDW: How important have screening technologies been in helping drive research towards more targeted therapeutic approaches?
Dr Stefano Gullà, CSO, Kling Bio: Screening technologies, such as genomic and proteomic, have been pivotal in identifying novel biomarkers and therapeutic targets. These technologies have enabled better understanding of the molecular underpinnings of blood cancers.
Dr Dongzhou Jeffery Liu, CEO, Heidelberg Pharma: Cancer treatments are generally more effective when administered early in disease progression. At this point, the cancer is still localised and has not yet spread to other parts of the body, making it possible to select treatments that are more effective and have fewer side effects. Therefore, early screening for cancer has the potential to improve patient care and reduce both mortality and morbidity associated with the disease. Cancer screening increasingly relies on advanced technologies to identify and characterise tumours.
Jeremy Skillington, CEO, Poolbeg Pharma: Screening technologies help to diagnose disease earlier, which is critical to achieve the best outcomes for patients, but they also allow us to learn more about disease biology which helps to find new, more effective treatments, or to identify which patients will respond well. In addition, screening technologies allow us to personalise treatments for each individual and ensure they are treated early.
Michael Lahn, CMO, iOnctura: Screening technologies to identify disease-driving mutations and actionable biomarkers with greater precision can aid the development of novel agents.
DDW: What other technologies have been crucial in enabling progress in this field?
Dr Stefano Gullà, CSO, Kling Bio: CRISPR-Cas9 gene editing has been instrumental in dissecting the genetic mechanisms of blood cancers. More work needs to be done to understand the interplay between blood cancer and the immune system, to tease out inhibitory signals that hamper immune response. Additionally, computational biology and AI-driven drug discovery platforms will play a key role in optimising therapeutic regimens.
Dr Dongzhou Jeffery Liu, CEO, Heidelberg Pharma: Essentially, three areas of research currently offer the most promising approaches.
Firstly, antibody drug conjugates (ADCs), whose triumph began in the 1990s. ADCs combine the selectivity of targeted antibodies with the cytotoxic efficacy of chemotherapeutic agents. The cytotoxic payload is released directly into the diseased cells and induces cell death. But first- and second-generation ADCs have a narrow therapeutic window – they cannot be administered at doses high enough to achieve optimal efficacy. Regardless of the target antigen and antibody, haematological and hepatic toxicities and neuropathy occurred in clinical trials, suggesting that the toxin was responsible for the dose-limiting side effects. As a result, toxins with new mechanisms of action were sought to overcome these limitations. Most ADCs currently in development are third-generation ADCs that use tubulin inhibitors and DNA-binding toxins as payloads.
Secondly, CAR-T cell therapy emerged in the late 2010s as a pioneering form of immunotherapy. It involves reprogramming a patient’s T cells to target and destroy cancerous cells. CAR-T cell therapy has demonstrated remarkable success in haematological malignancies, such as leukaemia, and is being investigated for wider application.
The third area involves bispecific antibodies, which simultaneously bind to targets on malignant plasma cells and cytotoxic immune effector cells (T cells or NK cells), forming an immunologic synapse. This leads to T-/NK-cell activation and destruction of malignant plasma cells.
Jeremy Skillington, CEO, Poolbeg Pharma: Technologies such as PCR, flow cytometry and DNA/RNA sequencing have supported a large proportion of the innovation to date. Using these technologies in a reliable validated method with high sensitivity and precision has been the bedrock of many proxy endpoints which have supported the development of new drugs. Synthetic biology has really propelled many of the immunotherapies such as bispecific antibodies and cell therapies. In addition, some very exciting products in development are using in vivo cell therapy and gene editing techniques.
Michael Lahn, CMO, iOnctura: Advances like next-generation sequencing, single-cell analysis, and AI-driven modelling are all contributions that are enabling researchers to uncover molecular targets, predict resistance and refine therapeutic strategies. These tools are likely to move from basic research to designing novel agents for the treatment of blood cancers.
DDW: Does more awareness need to be raised about blood cancers versus solid tumours?
Dr Stefano Gullà, CSO, Kling Bio: Yes, awareness of blood cancers needs to be raised, as they are often less visible than solid tumours but equally devastating. Public and clinical education is crucial to ensure early diagnosis, access to cutting-edge treatments, and funding for research – which is often skewed toward solid tumours.
Professor Andreas Pahl, CEO, Heidelberg Pharma: Certainly. Blood cancers have significantly lower public awareness compared to many solid tumours. Early-stage symptoms – such as swollen lymph nodes, fatigue, unexplained weight loss, frequent infections, night sweats, persistent itching or fever – are often overlooked or misinterpreted.
Unlike solid tumours, blood cancers are harder to treat as they are not confined to one region of the body or organ but instead affect the entire circulatory system.
Jeremy Skillington, CEO, Poolbeg Pharma: More awareness about blood cancers is urgently needed. Often referred to as the “hidden cancer”, blood cancers are less visible compared with solid tumours despite affecting hundreds of thousands of people worldwide each year and being just as life-threatening. Increasing awareness can improve early diagnosis, encourage research funding, and highlight the unique treatment advances and challenges in this field.
Michael Lahn, CMO, iOnctura: Yes – blood cancers often receive less public attention than solid tumours, perhaps because blood cancers are more complex. Raising awareness is vital to improve early diagnosis, research funding and access to emerging therapies for blood cancers. Because blood cancers are often considered rare the public should be made aware that blood cancer treatments have often informed treatments for more common cancers, including solid tumour malignancies.
DDW: What are some of the current therapeutic approaches driving innovation in blood cancers?
Dr Stefano Gullà, CSO, Kling Bio: Innovative approaches include CAR-T cell therapy, bispecific T-cell engagers (BiTEs), antibody-drug conjugates (ADCs), and targeted small molecule inhibitors like IDH and BCL-2 inhibitors. These therapies are transforming the treatment landscape by offering more effective and less toxic options for patients with blood cancers. We are also learning more about the ability of the immune system to identify new tumours antigens on leukaemic cells that might serve as targets for more potent therapeutics, an area in which Kling is actively involved.
Dr Dongzhou Jeffery Liu, CEO, Heidelberg Pharma Third-generation ADCs are particularly promising. Heidelberg Pharma has developed an ADC pipeline based on the toxin Amanitin and is the first company to use this toxin for the treatment of cancer.
Amanitin is one of the most advanced payloads developed for third-generation ADCs. Amatoxins are a group of cyclic peptides, which are actually found in the death cap mushroom (Amanita phalloides). They work by inhibiting RNA polymerase II, which leads to programmed cell death (apoptosis). Unlike other toxins, cell death occurs independently of cell division. This novel therapeutic approach offers the potential to overcome treatment resistance and destroy dormant tumour cells, which could lead to significant clinical advances.
Our lead Amanitin-based ADC candidate, HDP-101, is currently under investigation in a Phase I/IIa clinical trial for the treatment of relapsed or refractory multiple myeloma. Currently advancing in Cohort 9, The study has shown very encouraging results to date., Following the evaluation of Cohort 8, HDP-101 continues to be well tolerated and has demonstrated further clinical activity. A total of seven patients were evaluated in this cohort, and all patients demonstrated a favourable safety and tolerability profile throughout. Encouraging signs of clinical activity have also emerged. Four patients showed biological activity of HDP-101, with one partial response, one very good partial response and two stringent complete remissions (sCR). For sCR, no tumour cells are detectable in blood and bone marrow.
Jeremy Skillington, CEO, Poolbeg Pharma: Immunotherapies like CAR-T and bispecific antibodies are powerful treatments for blood cancers. However, they can trigger a serious side effect called cytokine release syndrome (CRS). CRS can affect more than 70% of patients undergoing CAR-T and bispecific antibody treatments. Currently, approved preventative therapies for CRS are lacking. At Poolbeg Pharma, we are developing POLB 001, an oral p38 MAPK targeting CRS prevention, which selectively prevents excessive inflammation without immunosuppression. POLB 001 could make cancer immunotherapy treatments safer and allow administration to expand beyond specialised cancer centres into the community hospital setting, by preventing this life-threatening side effect. POLB 001 has the potential to greatly expand patient access, improve healthcare capacity, and increase the overall market opportunity for cancer immunotherapies.
Michael Lahn, CMO, iOnctura: Targeted therapies have a successful track record in establishing practice-changing treatments. One such pathway that has been long recognised as a key driver of blood cancers is the PI3K pathway. This pathway consists of a family of different members, all of which were targeted by specific inhibitors. Until recently, one such family member, the PI3Kdelta, could not be blocked specifically. iOnctura has advanced roginolisib, a highly selective PI3Kdelta inhibitor, which promises to have the desirable selectivity profile and thus does not have the tolerability challenges of previous PI3K inhibitors.
To further confirm its early clinical safety profile, roginolisib is currently in clinical trials for chronic lymphocytic leukaemia (CLL) in a Phase I/II study investigating roginolisib + venetoclax + rituximab in relapsed / refractory CLL patients who previously received BTK inhibitors, sponsored by Dr Jennifer Brown at Dana-Farber Cancer Institute; peripheral T-cell lymphoma (PTCL) in a platform study evaluating roginolisib alone, sponsored by the French LYSARC network; and myelofibrosis in a Phase I/II study combining roginolisib with ruxolitinib for patients who have been unresponsive to JAK inhibitors.
